Fuics

Fuics has a pipeline with at least one asset in Phase 2 clinical development for chronic kidney disease. The company focuses on transforming pharmaceuticals from pre-clinical to commercial readiness, but no specific clinical results are disclosed in public sources. Fuics Ltd (also known as FUICS Development Ltd) is an active European biotech company headquartered in Limassol, Cyprus. The company specializes in developing new treatments for chronic kidney disease and aims to advance pharmaceuticals from preclinical stages through to commercial readiness. Its pipeline includes several assets with at least one program currently in Phase II clinical trials targeting chronic kidney disease. No specific details about drug modalities or molecular targets have been made public. There are no indications of acquisition or major partnerships as of now.